Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe
Bildiriler > Özet Bildiri
Yazarlar: Theodoros Karampitsakos, Nesrin MOĞULKOÇ BISHOP, Michael Kreuter, Wim Wuyts, Sara Tomassetti, Elisabeth Bendstrup, Maria Molina-Molina, Paolo Spagnolo, Effrosyni Manali, Ömer Selim UNAT, Nicolas Kahn, Lykourgos Kolilekas, Elisabetta Rosi, Leonardo Gori, Claudia Ravaglia, Zoe Daniil, Thomas Skovhus Prior, Ilias Papanikolaou, Samantha Aso, Stavros Tryfon, Despoina Papakosta, Elisabetta Balestro, Spyridon Papiris, Katerina Antoniou, Demosthenes Bouros, Argyris Tzouvelekis
Idiopathic interstitial pneumonias, , , Uluslararası, Özet Bildiri, ss OA1205-OA1205
DOI: 10.1183/13993003.congress-2021.oa1205
Özet
Background: Abundant evidence supports an association between Idiopathic Pulmonary Fibrosis (IPF) and lung cancer development. Data on diagnosis and management of patients with IPF and lung cancer are still scarce. Aim: To present clinical features of patients with IPF and lung cancer. Patients and Methods: This was a retrospective, multicenter study enrolling 3178 patients with IPF in Europe between 1/1/2019 and 31/1/2021. Results: We identified 324 patients with IPF and lung cancer [prevalence: 10.2%, median age: 71 years (95% CI: 70 to 71), males: 90.4%, mean FVC%predicted ±SD: 76.9 ± 20.1, mean DLCO%predicted ± SD: 45.8± 16.9]. Non-small cell lung cancer was identified in 73.5% of patients (squamous: 33.3%, adenocarcinoma: 26.9%, NOS: 13.3%), while 17.4% and 9.1% of patients were diagnosed with small cell lung cancer and other types of cancer, respectively. Lung cancer was diagnosed synchronously with IPF in 41.8% and post IPF diagnosis in 45.4% of cases with a median latency time of 28.1 months (95% CI: 20.3 to 32.7). The tumor was otherwise operable in 46.6% of cases (IA: 19.1%, IB: 13.5%, IIA: 2.2%, IIB: 10.1%, IIIA: 10.1%, IIIB: 11.2%, IIIC: 2.2%, IVA: 19.7%, IVB: 11.8%). Antifibrotics were prescribed in 50.9% of patients. Chemotherapeutic regimens other than nintedanib were applied in 46.2% of cases, while 28.3% of patients underwent surgery. Median survival was 21.4 months (95% CI: 18.8 to 26.5) from the time of lung cancer diagnosis. Conclusions: IPF represents a risk factor for lung cancer development. Disease management remains heterogeneous. Randomized controlled studies on the management of patients with IPF and lung cancer are greatly anticipated.